.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,977,099

« Back to Dashboard

Claims for Patent: 5,977,099

Title: Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
Abstract:The invention relates to a pharmaceutical composition comprising mirtazapine, a selective serotonin reuptake inhibitor (SSRI) and pharmaceutically acceptable auxiliaries. In particular the SSRI is selected from fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, sertraline, paroxetine, ifoxetine, cyanodothiepin and litoxetine. The composition which can be used to treat depressant patients has less side effects than treatment of the patients with mirtazapine or the SSRI alone.
Inventor(s): Nickolson; Victor Johannes (Hermelijnendreef, NL)
Assignee: Akzo Nobel, N.V. (Arnhem, NL)
Application Number:08/876,346
Patent Claims: 1. A combination comprising mirtazapine or a pharmaceutically acceptable salt thereof and at least one SSRI's or a pharmaceutically acceptable salt thereof.

2. The combination according to claim 1, wherein the SSRI is one selected from the group consisting of zimeldine, fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, ifoxetine, cyanodothiepin, sertraline, paroxetine, and litoxetine.

3. The combination according to claim 1, comprising mirtazapine and fluoxetine.

4. A pharmaceutical composition comprising an effective amount of a combination according to claim 1 in association with one or more pharmaceutically acceptable carriers therefor.

5. A method for the treatment of depression in an animal, which comprises treating said animal with a therapeutically effective amount of a combination as defined in claim 1.

6. A package containing separated dosage units, of which at least one dosage unit comprises mirtazapine and at least one other dosage unit comprises an SSRI.

7. The pharmaceutical composition according to claim 4, wherein the SSRI is at least one selected from the group consisting of zimeldine, fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, ifoxetine, cyanodothiepin, sertraline, paroxetine, and litoxetine.

8. The pharmaceutical composition according to claim 4, comprising mirtazapine and fluoxetine.

9. The method of claim 5, wherein the at least one SSRI's in said combination are selected from the group consisting of zimeldine, fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, ifoxetine, cyanodothiepin, sertraline, paroxetine, and litoxetine.

10. The method of claim 5, wherein the combination comprises mirtazapine and fluoxetine.

11. A method for the treatment of depression in an animal, which comprises treating said animal with a therapeutically effective amount of the pharmaceutical composition of claim 4.

12. The method of claim 11, which comprises treating said animal with a therapeutically effective amount of the pharmaceutical composition of claim 11.

13. The package according to claim 6, wherein the SSRI is fluoxetine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc